Hematologic Malignancy
Mantle Cell Lymphoma
CI-CAN-00005962MCLExplore in graph →
Hematologic180 active trials5 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005962MCLExplore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00644189 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma |
| completed |
| Phase 1 / Phase 2 |
| 50 |
| Massachusetts General HospitalOTHER |
| 1 |
| Mar 15, 2023 |
| clinicaltrials |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | withdrawn | Phase 1 | 0 | HutchmedINDUSTRY | 7 | Feb 21, 2023 | clinicaltrials |
| NCT03836768 | BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma | completed | Phase 1 | 20 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02257242 | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma(BRiM) | completed | Phase 1 | 11 | Brown UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03877055 | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT03019666 | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | completed | Phase 1 | 39 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | completed | Phase 1 / Phase 2 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02756247 | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | completed | Phase 1 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | withdrawn | Phase 1 | 0 | Yazeed SawalhaOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02049541 | Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 1 | 18 | Kami Maddocks, MDOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT01865617 | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 204 | Fred Hutchinson Cancer CenterOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT02419560 | Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | completed | Phase 1 | 37 | Craig Portell, MDOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT03682796 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | completed | Phase 1 | 32 | Triphase Research and Development III Corp.INDUSTRY | 2 | May 19, 2022 | clinicaltrials |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | terminated | Phase 1 | 2 | Eden BioCell Ltd.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | terminated | Phase 1 | 10 | TG Therapeutics, Inc.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05003141 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | unknown | Phase 1 | 110 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics)INDUSTRY | 3 | Mar 28, 2022 | clinicaltrials |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 58 | Swiss Cancer InstituteOTHER | 3 | Mar 11, 2022 | clinicaltrials |
| NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | terminated | Phase 1 | 7 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 68 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | terminated | Phase 1 | 13 | ADC Therapeutics S.A.INDUSTRY | 2 | Oct 26, 2021 | clinicaltrials |
| NCT01381692 | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 4, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | terminated | Phase 1 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00406809 | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 81 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Aug 2, 2021 | clinicaltrials |
| NCT02650999 | Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas | completed | Phase 1 / Phase 2 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT00794638 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 9 | SymBio PharmaceuticalsINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | terminated | Phase 1 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | terminated | Phase 1 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | terminated | Phase 1 / Phase 2 | 39 | Sunesis PharmaceuticalsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01921387 | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2023source: clinicaltrials